AutoNation CEO Is Open to Selling Tesla Vehicles and 2 More Heavily Traded Stocks to Follow
Tesla Motors Inc. (NASDAQ:TSLA): Current price $169.93
AutoNation Chairman and Chief Executive Mike Jackson commented that Tesla Motors only sells its “marvelous product” directly, but if it ever transitions to a retail model, his company would be “completely open” to selling its vehicles. Speaking on CNBC’s Squawk Box on Thursday, Jackson observed that, “It’s an excellent electric car. If you take the Fisker, which was a terrible car, the company is now bankrupt. You take Tesla, which is an outstanding car, and the company is really finding its way.”
Comcast Corp. (NASDAQ:CMCSA): Current price $42.54
As the new school year kicks off, Comcast is re-launching Internet Essentials, marking the country’s biggest and most comprehensive broadband adoption initiative for low-income families. This autumn is the program’s third season and in the 22 months since the program was first debuted, benefitting an estimated 900,000 low-income Americans spanning the United States, with over 220,000 families now with a broadband connection at home.
This number includes 6,300 families and over 25,000 individuals in Oregon and SW Washington. Comcast employees are distributing backpacks at Cesar Chavez Elementary School in Portland as part of the Tools For Schools Program with Schoolhouse Supplies, and is one in a series of back to school events which Comcast is hosting in 23 states nationwide to increase visibility about bridging the digital divide in America and linking more families to the Internet.
Rockwell Medical Inc. (NASDAQ:RMTI): Current price $7.99
On Thursday, Rockwell said that its lead experimental drug attained the main goal of improving hemoglobin levels in its final late-stage trial among adult patients suffering with chronic kidney disease. The evaluation was the second of two identical late-stage studies testing the drug in patients having chronic kidney disease on hemodialysis, a process by which waste and extra fluid is removed from the blood of patients with kidney failure.
Analyst Carol Werther at Summer Street Research predicted that Rockwell would be able to file for marketing approval within four to six months and that the drug, Soluble Ferric Pyrophosphate, was likely to be okayed in the second half of next year.